Viral infection

Phase 3 trial of Novavax investigational COVID-19 vaccine opens

In animal tests, NVX-CoV2373 vaccination produced antibodies that blocked the coronavirus spike protein from binding to the cell surface receptors targeted by the virus, preventing viral infection